COLL — Collegium Pharmaceutical, Inc. · 2026-09-04 · Verdict: WATCH · Conviction 2
Price $23.70 · Mkt cap ~$735M (31.0M sh post-ASR) · EV ~$1.71B · EV/2026E adj EBITDA 3.7x · 2025 FCF $327.6M · Net debt $977.5M (2.1x) · ADV ~$20M Sources read: 10-K 2026-02-26 (Items 1, 1A, 7), 10-Q 2026-08-06, DEF 14A 2026-04-07, 8-Ks 2026-03-19 / 05-12 / 08-06 / 08-13, Form 4s (12m), Q2 2026 call transcript with Q&A (Alpha Vantage).
1. What the business actually does
Collegium sells six branded medicines in the US with its own sales force. Two are ADHD stimulants: Jornay PM, the only FDA-approved evening-dosed stimulant, acquired with Ironshore in September 2024, and Azstarys, bought from Corium for roughly $655M net of cash in May 2026 (10-Q Q2 2026, MD&A). Four are pain assets: Belbuca, Xtampza ER, Nucynta and Symproic. There is no pipeline: this is a cash-collection machine funded with debt.
2. Why it is mispriced: the edge case, and the correction that kills the framing
The intended edge is a misunderstood segment, and consolidated revenue up 6% does hide ADHD compounding at 41% while pain melts. But the screen that flagged this name computed enterprise value of $881M by counting only the convertible notes and missing the term loan. At June 30, 2026 the structure is $865.5M of 2025 Term Loan plus $241.5M of 2029 Convertible Notes against $129.5M of cash, so net debt is $977.5M and enterprise value roughly $1.71B (10-Q Q2 2026, MD&A), which the CFO's 2.1x net debt to adjusted EBITDA confirms (Q2 call, CFO). The right question is whether ADHD plus a decaying pain annuity justifies $1.71B.
Second correction: Jornay PM is protected by sixteen US patents projected to expire in 2032, not 2037 (10-K FY2025, Item 1). The 2037 date belongs to Azstarys alone (Q2 call, CEO). The growth engine has six years of exclusivity, not eleven.
3. Unit economics
2025: revenue $780.6M, operating cash flow $329.3M against $1.7M of capex, adjusted EBITDA $460.5M (10-K FY2025, Item 7). The $221.9M of amortization is purchase accounting on acquired products, and cash flow struck after roughly $70M of cash interest corroborates adjusted EBITDA. The $82.3M of interest is real, and the Q2 GAAP loss of $15.1M is $24.1M of Azstarys transaction costs plus $63.0M of amortization (10-Q Q2 2026, MD&A).
Segment math from the 2026 guide (midpoint $840M revenue, $457.5M adjusted EBITDA, adjusted opex $282M, cash COGS $95M): ADHD is roughly $265M of revenue carrying about $120M of selling cost across 190 reps, contributing about $110M. Pain is roughly $575M with far lower selling cost, contributing about $420M. Almost all of today's cash comes from the run-off asset: you are not buying ADHD with a free annuity, you are buying an annuity that pays for an ADHD build-out.
4. Balance sheet and capital allocation
The December 2025 Truist facility is a $580M term loan, $300M delayed draw (drawn in May 2026 for Azstarys) and an undrawn $100M revolver at SOFR plus 2.75% to 3.75%, 3.25% at close (8-K 2026-06-30, EX-99). Only $55.0M amortizes in the next twelve months, so deleveraging is discretionary and slow. Shares grew from 31.5M to 32.6M, then on August 12 Collegium signed a $50M accelerated repurchase at $25.70, initial delivery 1,556,420 shares under the $150M authorization (8-K 2026-08-13), offsetting a year of dilution rather than shrinking the base. Alignment is weak: officers and directors own 1.85%, the CEO 71,707 shares (DEF 14A 2026), and insiders bought nothing in twelve months while selling $7.2M.
5. Management: said versus did
Guidance of $865M to $895M revenue and $475M to $500M adjusted EBITDA was cut two quarters later to $825M to $855M and $445M to $470M (8-K 2026-08-06), entirely on Nucynta authorized generic pricing: on AG volume Collegium nets only 10% to 15% of branded Nucynta IR price and 20% to 25% of branded ER, which the CFO said "has stabilized at this point." Jornay guidance held and Azstarys was raised, with the CEO denying stocking effects. The key disclosure was Belbuca: Teva can launch a generic in January 2027 under a settlement, management does not believe that fits Teva's strategy, an AG agreement is in place, and Alvogen is barred until December 2032. Xtampza is settled to September 2033 (Q2 call, CFO).
6. Valuation
Base ($30, 50%): Nucynta near zero by 2029, Belbuca holds through 2027 then erodes, Xtampza declines mid single digits, ADHD reaches roughly $400M by 2029. Unlevered free cash flow of about $375M in 2026 drifts to $310M by 2029 and steps down at Jornay's 2032 expiry; at 11% with an Azstarys-anchored terminal value, EV about $1.95B less net debt.
Bear ($10, 30%): Teva launches Belbuca in January 2027, the AG triggers, Belbuca contribution falls 60% in year one and Jornay plateaus near $220M. Adjusted EBITDA falls toward $330M, leverage passes 3x, and the equity becomes an option on refinancing the converts.
Bull ($52, 20%): no Belbuca generic before 2032, Jornay above $300M and Azstarys above $150M by 2029, ADHD margin scales and the multiple rerates to 6x. Probability-weighted value is $28.40 against $23.70, about 20% upside against a 58% downside. That asymmetry is not good enough.
Reverse DCF: at $23.70 the $1.71B enterprise value implies unlevered free cash flow declining about 11% a year in perpetuity from $375M, meaning the market already prices the whole company as a run-off with no terminal value credited to ADHD beyond Jornay's 2032 patents.
7. Catalysts and timeline
Back-to-school scripts land in Q3 results (November 2026). Nucynta IR pediatric exclusivity lapses January 3, 2027 and the Teva Belbuca window opens the same month. February 2027 guidance is the first clean look at post-Nucynta earning power. Management is hunting another $300M to $500M peak-sales asset (Q2 call, CEO), which at 2.1x leverage means more debt.
8. Risks and pre-registered kill criteria
- Belbuca net revenue falls below $40M in a quarter, versus $57.7M in Q2 2026.
- Jornay plus Azstarys combined revenue fails to exceed $75M in any quarter through Q2 2027, versus $59.0M in Q2 2026.
- Net debt to adjusted EBITDA exceeds 2.75x for two consecutive quarters, from 2.1x.
- Management guides 2027 adjusted EBITDA below $400M.
9. Verdict and one-paragraph summary
WATCH, conviction 2. Collegium looks like a 3.7x EBITDA stub and the ADHD franchise is genuinely working: Jornay grew 41% to $46.1M with prescribers above 30,000 and 29.2% share of the branded long-acting methylphenidate market, and Azstarys guidance rose in its first partial quarter (Q2 call, CEO). But the cheapness that flagged this name came from a screen that missed the $865.5M term loan, so enterprise value is $1.71B, not $881M, and once you fix that the run-off arithmetic barely covers the debt. Nearly all cash flow comes from the pain portfolio, which management is running off to fund an ADHD build-out whose lead asset loses patent protection in 2032. Management just cut guidance on Nucynta pricing it had misjudged, insiders own 1.85% and have bought nothing, and the thesis pivots on one dated binary: whether Teva launches a generic Belbuca in January 2027. Wait for it, or for a price near $15 where the bear case is paid for.
Research for discussion, not investment advice. Positions and sizing are the reader's decision.